Renal Osteodystrophy — 12-month Study of AMG 073 in Renal Osteodystrophy
Citation(s)
A Multicenter, Randomized, Placebo-controlled, Double-blind, 12-month Study to Assess the Effects of an Oral Calcimimetic Agent (AMG 073) on Renal Osteodystrophy in Hemodialysis Patients With Secondary Hyperparathyroidism